{"id":167877,"date":"2026-09-16T21:33:22","date_gmt":"2026-09-16T21:33:22","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/167877\/"},"modified":"2026-09-16T21:33:22","modified_gmt":"2026-09-16T21:33:22","slug":"novo-nordisk-partners-with-anthropic-to-apply-ai-to-drug-discovery-and-research","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/167877\/","title":{"rendered":"Novo Nordisk Partners With Anthropic to Apply AI to Drug Discovery and Research"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/819665e50d76820b63babfa5408b04c38612ca9d3c956d6ebfef68c8613d5205\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Finvestorshub_458%2Fe64f825aefcc040e8303052f4f2ea010.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Researcher looking through microscope \u00a9gebakax\" height=\"527\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Researcher looking through microscope \u00a9gebakax           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk (NYSE:NVO) has announced a collaboration with artificial intelligence company Anthropic to integrate AI models into its drug discovery, research and development, and software engineering activities.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The partnership will combine Anthropic&#8217;s AI technology with Novo Nordisk&#8217;s scientific expertise to investigate how AI can support biological reasoning, address research problems and improve R&amp;D workflows.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The companies did not disclose the financial terms of the agreement.  <\/p>\n<p>        Novo Nordisk to Test Claude Science in R&amp;D          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Under the agreement, Novo Nordisk will use Anthropic&#8217;s AI models and Claude Science to support scientific reasoning in research and development.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The pharmaceutical company plans to begin by testing Claude Science on selected scientific problems and R&amp;D workflows where it believes the technology could provide measurable benefits.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The initial work will assess how AI can assist researchers in analysing complex biological information and carrying out scientific tasks.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk has not disclosed specific drug candidates or clinical development programmes associated with the collaboration.  <\/p>\n<p>        Companies Target Research Productivity          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk President and Chief Executive Officer Mike Doustdar said the agreement forms part of the company&#8217;s broader adoption of AI technologies.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;This partnership is another testament to our ambition to become the world&#8217;s most AI-driven healthcare company, building on Novo&#8217;s current AI initiatives with other technology partners,&#8221; Doustdar said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;AI can help us increase productivity in R&amp;D and compress the path from research to marketed product.&#8221;  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Anthropic co-founder and Chief Executive Officer Dario Amodei said the collaboration aims to reduce research timelines and improve outcomes.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The companies have not provided quantitative targets for productivity improvements or reductions in drug development timelines.  <\/p>\n<p>        Collaboration Extends to Software Engineering          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Beyond scientific research, Novo Nordisk plans to use Anthropic&#8217;s AI models to support software development across its operations.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The agreement includes applications involving agentic software engineering, in which AI systems can assist with sequences of development tasks.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk said the collaboration will incorporate data governance and human oversight measures intended to align the use of AI with its ethical and compliance requirements.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The announcement did not specify an implementation timetable for the broader software engineering applications.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The partnership adds Anthropic to Novo Nordisk&#8217;s existing technology collaborations as the pharmaceutical company expands its use of AI in research and internal operations.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk stock price  <\/p>\n","protected":false},"excerpt":{"rendered":"Researcher looking through microscope \u00a9gebakax Novo Nordisk (NYSE:NVO) has announced a collaboration with artificial intelligence company Anthropic to&hellip;\n","protected":false},"author":2,"featured_media":167878,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[34067,1204,77856,272,32563,7512,77971,21619,4747],"class_list":["post-167877","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-anthropic","tag-artificial-intelligence","tag-claude-science","tag-novo-nordisk","tag-pharmaceutical-company","tag-research-and-development","tag-scientific-reasoning","tag-scientific-research","tag-software-engineering"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117282865562874745","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/167877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=167877"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/167877\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/167878"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=167877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=167877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=167877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}